For research use only. Not for therapeutic Use.
Selumetinib sulfate（Cat No.:I017656）is a potent, selective inhibitor of MEK1 and MEK2, key components of the MAPK/ERK signaling pathway that regulates cell proliferation and survival. By blocking MEK activity, Selumetinib effectively inhibits downstream ERK phosphorylation, reducing tumor growth and promoting apoptosis in cancers with dysregulated MAPK signaling. It is approved for the treatment of neurofibromatosis type 1 (NF1) and is being investigated in various cancers, including melanoma, thyroid, and lung cancer. Selumetinib sulfate is a valuable tool for studying MEK inhibition in targeted cancer therapies and tumor growth suppression.
| Catalog Number | I017656 |
| CAS Number | 943332-08-9 |
| Molecular Formula | C₁₇H₁₇BrClFN₄O₇S |
| Purity | ≥95% |
| IUPAC Name | 6-(4-bromo-2-chloroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide;sulfuric acid |
| InChI | InChI=1S/C17H15BrClFN4O3.H2O4S/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19;1-5(2,3)4/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26);(H2,1,2,3,4) |
| InChIKey | GRKFGZYYYYISDX-UHFFFAOYSA-N |
| SMILES | CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)Cl)C(=O)NOCCO.OS(=O)(=O)O |
| Reference | [1]. [1].Huynh H, et al, Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma. Mol Cancer Therapy, 2007, 6 (1), 138-146<br>[2]. [2].Garon EB, et al. Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines. Mol Cancer Thera, 2010, 9 (7), 1985-1994.<br>[3]. [3].Yeh TC, et al. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res, 2007, 13 (5), 1576-1583. |
